[Comment] MiStent: just another example of non-inferiority?

The Xience everolimus-eluting coronary stent has been shown to reduce the risk for stent thrombosis and target-lesion revascularisation compared with first-generation drug-eluting stents.1 In recent trials of drug-eluting stents, several other new-generation stents, such as Resolute zotarolimus-eluting stent,2 Nobori biolimus-eluting stent,3 Synergy everolimus-eluting stent,4 Ultimaster sirolimus-eluting stent,5 and Orsiro sirolimus-eluting stent,6 were non-inferior to Xience for target-lesion failure; however, no new-generation drug-eluting stent has shown superiority over Xience.
Source: LANCET - Category: General Medicine Authors: Tags: Comment Source Type: research